Loading
A phase 1/2 trial of QLC5508, Abiraterone acetate, Enzalutamide in prostate cancer, run by Qilu Pharmaceutical Co., Ltd., now recruiting.
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer is a phase 1/2 interventional study registered as NCT07198633 by Qilu Pharmaceutical Co., Ltd., with 212 participants planned, started 2025-11-05 and due to reach its primary completion in 2026-12. Interventions recorded: QLC5508, abiraterone acetate, enzalutamide, QLH12016. Conditions listed: Advanced Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares QLC5508, Qilu Pharmaceutical.
Shares QLC5508, Qilu Pharmaceutical.
Shares QLC5508, Qilu Pharmaceutical.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/